The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Immunovant Inc’s stock clocked out at $25.35, down -1.02% from its previous closing price of $25.61. In other words, the price has decreased by -$1.02 from its previous closing price. On the day, 1.18 million shares were traded. IMVT stock price reached its highest trading level at $25.605 during the session, while it also had its lowest trading level at $24.95.
Ratios:
To gain a deeper understanding of IMVT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.07 and its Current Ratio is at 9.07. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on October 14, 2025, initiated with a Hold rating and assigned the stock a target price of $16.
On March 03, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $20.Jefferies initiated its Hold rating on March 03, 2025, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 18 ’25 when Van Tuyl Christopher sold 10,813 shares for $26.91 per share. The transaction valued at 290,943 led to the insider holds 149,930 shares of the business.
Roivant Sciences Ltd. bought 16,666,666 shares of IMVT for $349,999,986 on Dec 12 ’25. The Director now owns 113,317,007 shares after completing the transaction at $21.00 per share. On Dec 01 ’25, another insider, Fromkin Andrew J., who serves as the Director of the company, sold 22,249 shares for $23.25 each. As a result, the insider received 517,189 and left with 85,852 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 5107429888 and an Enterprise Value of 3921389824.
Stock Price History:
The Beta on a monthly basis for IMVT is 0.58, which has changed by 0.016673326 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, IMVT has reached a high of $27.69, while it has fallen to a 52-week low of $12.72. The 50-Day Moving Average of the stock is 7.34%, while the 200-Day Moving Average is calculated to be 41.54%.
Shares Statistics:
It appears that IMVT traded 1.78M shares on average per day over the past three months and 1970990 shares per day over the past ten days. A total of 174.53M shares are outstanding, with a floating share count of 83.65M. Insiders hold about 58.48% of the company’s shares, while institutions hold 47.70% stake in the company. Shares short for IMVT as of 1765756800 were 14964704 with a Short Ratio of 8.43, compared to 1763078400 on 16381611. Therefore, it implies a Short% of Shares Outstanding of 14964704 and a Short% of Float of 17.21.
Earnings Estimates
As of right now, 9.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.7, with high estimates of -$0.57 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$2.33 and -$3.34 for the fiscal current year, implying an average EPS of -$2.93. EPS for the following year is -$3.0, with 11.0 analysts recommending between -$1.96 and -$3.98.
